• MJHLS Brand Logo

© 2020 MJH Life Sciences™ and Rheumatology Network. All rights reserved.

Sjögren Syndrome: Updates From ACR 2018

October 20, 2018
Gregory M. Weiss, MD

What’s new in Sjögren syndrome: (1) clinical clues herald progression to a life-threatening variant and (2) a common therapy exacerbates comorbidities.

References1. Retamozo S, Flores-Chavez A, Kostov B, et al. Severe, Life-Threatening Phenotype of Primary Sjögren Syndrome: Clinical Characterization and Outcomes in 1580 Patients (GEAS-SS Registry) [Abstract 1564]. Arthritis Rheumatol. 2018;70(suppl 10). Accessed October 22, 2018.2. Baldini C, Ferro F, Luciano N, et al. Comorbidity Burden in Primary Sjögren’s Syndrome: A Long-Term Observation in Clinical Practice [Abstract 1565]. Arthritis Rheumatol. 2018;70(suppl 10). Accessed October 22, 2018.This information is brought to you by Rheumatology Network and is not sponsored by, nor a part of, the American College of Rheumatology.

Two studies presented at the American College of Rheumatology (ACR 2018) annual meeting in Chicago, IL, address the outcomes and comorbidities associated with Sjögren syndrome. In the first study, Retamozo and colleagues in Spain found that 13% of patients with Sjögren syndrome develop systemic disease-leading to death in as many as 20%.1 In the second study, Baldini and fellow researchers in Italy discovered that glucocorticoid therapy exacerbates comorbidities in patients with primary Sjögren syndrome.2 Scroll through the slides for the details of the two studies and the take-home points for clinicians.

ESSDAI, European League Against Rheumatism Sjögren’s Syndrome Disease Activity Index.

DMARD, disease-modifying antirheumatic drug; ESSDAI, European League Against Rheumatism Sjögren’s Syndrome Disease Activity Index.

PreviousNext